Volume 13, Number 6—June 2007
Research
Isolation and Characterization of Novel Human Parechovirus from Clinical Samples
Kanako Watanabe*†, Masayasu Oie*, Masaya Higuchi*, Makoto Nishikawa†, and Masahiro Fujii*
Table 1
Neutralization activities of anti-HPeV antibodies using Vero cells*
| Antiserum | Virus |
|||
|---|---|---|---|---|
| NII561-2000 | HPeV-1 | HPeV-2 | HPeV-3 | |
| NII561-2000 | 160 | 10 | <10 | <10 |
| HPeV-1† | <10 | >1,280 | <10 | <10 |
| HPeV-2 | <10 | <10 | 160 | <10 |
| HPeV-3 | <10 | <10 | <10 | >1,280 |
*HPeV, human parechovirus.
†The HPeV strains used were Harris strain for HPeV-1, Williamson strain for HPeV-2, and A308/99 for HPeV-3.
Page created: June 16, 2011
Page updated: June 16, 2011
Page reviewed: June 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.